Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Man Group plc

Man Group plc reduced its position in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 21.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 102,021 shares of the company's stock after selling 27,588 shares during the period. Man Group plc owned about 0.17% of Twist Bioscience worth $4,741,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Barclays PLC increased its holdings in Twist Bioscience by 214.8% during the 3rd quarter. Barclays PLC now owns 153,039 shares of the company's stock valued at $6,913,000 after acquiring an additional 104,420 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of Twist Bioscience by 19.9% in the fourth quarter. Blue Trust Inc. now owns 4,567 shares of the company's stock valued at $206,000 after purchasing an additional 757 shares in the last quarter. KBC Group NV grew its position in shares of Twist Bioscience by 71.4% in the fourth quarter. KBC Group NV now owns 2,942 shares of the company's stock valued at $137,000 after purchasing an additional 1,226 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Twist Bioscience by 11.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 12,586 shares of the company's stock valued at $585,000 after purchasing an additional 1,318 shares during the last quarter. Finally, Jennison Associates LLC increased its stake in shares of Twist Bioscience by 80.2% during the 4th quarter. Jennison Associates LLC now owns 680,778 shares of the company's stock worth $31,636,000 after purchasing an additional 302,884 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. JPMorgan Chase & Co. reduced their target price on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. The Goldman Sachs Group cut their price target on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Robert W. Baird reduced their price objective on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Finally, Guggenheim reissued a "buy" rating and issued a $50.00 target price on shares of Twist Bioscience in a research note on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $50.40.

Twist Bioscience Trading Up 1.9%

Twist Bioscience stock traded up $0.55 during trading on Tuesday, hitting $28.81. The company's stock had a trading volume of 101,895 shares, compared to its average volume of 974,046. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. The stock has a market capitalization of $1.73 billion, a price-to-earnings ratio of -8.50 and a beta of 2.54. The stock's fifty day moving average is $36.44 and its 200 day moving average is $42.69. Twist Bioscience Co. has a 1-year low of $27.12 and a 1-year high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. As a group, equities research analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current year.

Insider Buying and Selling at Twist Bioscience

In other news, COO Patrick John Finn sold 2,800 shares of Twist Bioscience stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $37.65, for a total value of $105,420.00. Following the transaction, the chief operating officer now directly owns 262,660 shares of the company's stock, valued at $9,889,149. The trade was a 1.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Emily M. Leproust sold 2,402 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $98,265.82. Following the sale, the chief executive officer now directly owns 662,692 shares of the company's stock, valued at approximately $27,110,729.72. This trade represents a 0.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 26,011 shares of company stock worth $951,499 in the last quarter. 3.01% of the stock is owned by insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.